Skip to content

Outcome of a Triple Inner Branched Aortic Arch Stentgraft. A Prospective, Multicenter Registry.

Outcome of a Triple Inner Branched Aortic Arch Stentgraft. A Prospective, Multicenter Registry.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05530304
Acronym
triple_branch
Enrollment
30
Registered
2022-09-07
Start date
2023-02-09
Completion date
2027-03-31
Last updated
2023-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Arch, Aortic Arch Aneurysm, Dissection of Aortic Arch, Triple Branch

Keywords

Aortic arch pathologies, Aortic arch aneruysm, Aortic arch dissection, triple branch, stentgraft, Double branch, Inner branch

Brief summary

Outcome of a triple inner branched aortic arch stentgraft. A prospective, mulitcenter registry.

Interventions

DEVICETriple inner branched arch stentgraft

New findings regarding treatment planning and management of patients with aortic arch pathologies.

Sponsors

University Hospital Muenster
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* 18 years or older * Presence of Aortic arch pathology * Treatment planned with triple inner branch from Terumo Aortic * Availability of the patients during the follow up period * Informing patients about the study and providing written informed consent

Exclusion criteria

* Women of childbearing age * Patients under 18 years

Design outcomes

Primary

MeasureTime frame
feasibility in terms of cannulation and stentgrafting of the three branchesDuring intervention
Stroke30 days after intervention
Mortality30 days after intervention

Secondary

MeasureTime frameDescription
Patency rate of branchesduring the follow up period of 3 yearprimary and secondary
Morbidityduring the follow up period of 3 yearAccess issue, paraplegia, kidney failure
Strokeduring the follow up period of 3 year
Endoleaks Type I and IIIduring intervention and the follow up period of 3 year
Longterm mortalityduring the follow up period of 3 year

Countries

Germany

Contacts

Primary ContactAlexander Oberhuber, MD, PhD
alexander.oberhuber@ukmuenster.de+49 251 8345781
Backup Contactvascular trial unit
vital@ukmuenster.de+49 251 8351717

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026